Skip to Content

'
Peter Y. Kim, MD, FACC

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Director of ECG and Holter Monitoring, Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Medical Director, Cardiac Monitoring, Department of Cardiology, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2002 Texas A&M University, College Station, TX, BS, Biomedical Science
2002 Texas A&M University, College Station, TX, MD, Medicine

Postgraduate Training

2008-2010 Cardiology Externship, Cardiology, University Medical and Dental Schools of New Jersey and Cardiovascular Associates of Delaware Valley, Various, NJ
2008-2009 Hospital Extern, New Jersey Community Hospitals, Various, NJ
2007-2010 Clinical Fellowship, Cardiovascular, Cooper University Hospital, Camden, NJ
2004-2007 Clinical Residency, Internal Medicine, UMDNJ-Robert Wood Johnson University Hospital, New Brunswick, NJ

Board Certifications

10/2011 Board of Echocardiography
10/2010 Cardiovascular Disease
12/2009 Board of Nuclear Cardiology
8/2007 American Board of Internal Medicine

Honors and Awards

2012 Clinical Safety and Effectiveness Program Graduate (Team Leader) Session 16, The University of Texas MD Anderson Cancer Center
2009-2010 Chief Cardiology Fellow, Cooper University Hospital
1998-2004 Medical Science Scholar, Texas A&M University
1998-2002 President's Endowed Scholarship, Texas A&M University
1998 National Merit Scholarship Recipient, Texas A&M University

Selected Publications

Letters to the Editor

1. Yusuf SW, Kim P, Durand JB. Erlotinib or Gefitinib for Non-Small-Cell Lung Cancer. New England Journal of Medicine 364(24):2367, 6/2011.

Last updated: 7/1/2014